Skip to main content

Advertisement

SpringerLink
Log in

Platinum-based chemotherapy in triple-negative advanced breast cancer

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

An Erratum to this article was published on 26 March 2015

Abstract

The purpose of this study was to evaluate the efficacy of platinum-based chemotherapy (PBC) versus conventional non-PBC regimens in a metastatic triple-negative breast cancer (TNBC) setting. We reviewed the electronic patient records of patients with confirmed metastatic TNBC at four major cancer centres in Canada. All patients were allocated into two groups based on type of chemotherapy received (PBC vs. non-PBC) and line of treatment (first-, second-, or third-line). The primary objective of this study was to evaluate the efficacy of PBC in metastatic TNBC in terms of median duration of overall survival (OS) from diagnosis of distant metastatic disease and compare it with the efficacy of conventional non-platinum-based chemotherapy in metastatic TNBC after controlling for known prognostic factors. A total of 153 metastatic TNBC patients were identified, 58 treated with PBC and 95 with non-PBC. The median time in first-line PBC versus non-PBC was not different between the two groups (2 vs. 2 months, p = 0.9), the median time on treatment in second and third-line therapy was longer for the PBC group compared to the conventional treated group (4 vs. 1 months, p = 0.004; 4 vs. 0.5 months, p = 0.004, respectively). Patients who received PBC had a longer OS compared to those managed conventionally (14.5 vs. 10 months, p = 0.041). This study evaluates the survival outcomes in a homogenous group of TNBC metastatic patients treated with or without PBC. Our results confirmed our hypothesis of a better OS among PBC-treated TNBC patients compared to conventionally managed TNBC patients. Currently ongoing Phase III trials assessing the benefit of PBC versus other chemotherapeutic regimens in advanced TNBC will help define the role of these agents for the management of this breast cancer subtype.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434

    Article  PubMed  Google Scholar 

  2. Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657

    Article  PubMed  Google Scholar 

  3. Kassam F, Enright K, Dent R et al (2009) Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 9:29–33

    Article  PubMed  Google Scholar 

  4. Lin NU, Claus E, Sohl J et al (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113:2638–2645

    Article  PubMed Central  PubMed  Google Scholar 

  5. Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685

    Article  CAS  PubMed  Google Scholar 

  6. Toft DJ, Cryns VL (2011) Minireview: basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol 25:199–211

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4:814–819

    Article  CAS  PubMed  Google Scholar 

  8. Kim T, Lee H, Han S et al (2010) The comparison of the benefits obtained from platinum-containing chemotherapy between triple-negative and non-triple-negative metastatic breast cancer. J Clin Oncol 28:1071

  9. Koshy N, Quispe D, Shi R et al (2010) Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 19:246–248

    Article  PubMed  Google Scholar 

  10. Sirohi B, Arnedos M, Popat S et al (2008) Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19:1847–1852

    Article  CAS  PubMed  Google Scholar 

  11. Staudacher L, Cottu PH, Dieras V et al (2011) Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 22:848–856

    Article  CAS  PubMed  Google Scholar 

  12. Uhm JE, Park YH, Yi SY et al (2009) Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer 124:1457–1462

    Article  CAS  PubMed  Google Scholar 

  13. Bhattacharyya Gs BS, Agarwal V et al (2009) Single institute phaseII study of weekly cisplatinum and metronomic dosing of cyclophosphamide and methotrexate in second line metastatic breast cancer triple-negative. EJC suppl 7:18–19

    Article  Google Scholar 

  14. Fan Y, Xu BH, Yuan P et al (2012) P5-19-04: Results of a Randomized Phase II Study Demonstrate Benefit of Platinum-Based Regimen in the First-Line Treatment of Triple Negative Breast Cancer (TNBC). Cancer Research 71:P5-19-04

  15. Isakoff SJ, Goss PE, Mayer EL et al (2011) TBCRC009: a multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. J Clin Oncol 29:1025

  16. Wang Z, Hu X, Chen L et al (2010) Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: preliminary results report of a phase II trial. J Clin Oncol 28:1100

  17. Verma S, Provencher L, Dent R (2011) Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Curr Oncol 18:180–190

    PubMed Central  CAS  PubMed  Google Scholar 

  18. O’shaughnessy J, Osborne C, Pippen JE et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205–214

    Article  PubMed  Google Scholar 

  19. Baselga J, Stemmer S, Pego A et al (2011) Abstract PD01-01: cetuximab + cisplatin in estrogen receptor-negative, progesterone receptor-negative, her2-negative (triple-negative) metastatic breast cancer: results of the randomized phase ii bali-1 trial. Cancer Res 70:PD01-01

  20. Cameron D, Brown J, Dent R et al (2012) Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer. Cancer Res 72:S6-5

  21. Turner NC, Reis-Filho JS (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25:5846–5853

    Article  CAS  PubMed  Google Scholar 

  22. Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785–3790

    Article  CAS  PubMed  Google Scholar 

  23. Decatris MP, Sundar S, O’byrne KJ (2004) Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 30:53–81

    Article  CAS  PubMed  Google Scholar 

  24. Khalaf D, Hilton JF, Clemons M et al (2014) Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. Oncol Lett 7:866–870

    PubMed Central  CAS  PubMed  Google Scholar 

  25. O’shaughnessy J, Schwartzberg LS, Danso MA et al (2011) A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 29:1007

  26. Hurley J, Reis IM, Rodgers SE et al (2013) The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat 138:783–794

    Article  CAS  PubMed  Google Scholar 

  27. Von Minckwitz G, Schneeweiss A, Salat C et al (2013) A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). J Clin Oncol 31:1004

  28. Ding L, Ellis MJ, Li S et al (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999–1005

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Peddi PF, Ellis MJ, Ma C (2012) Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer 2012:217185

    Article  PubMed Central  PubMed  Google Scholar 

  30. Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750–2767

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Instituto Nacional de Cancerología, Ciudad de México, Mexico

    Cynthia Villarreal-Garza & Omar Peña-Curiel

  2. Sunnybrook Odette Cancer Centre, Toronto, Canada

    Cynthia Villarreal-Garza, Alexander Kiss, Sunil Verma, Kathleen Pritchard & Rebecca Dent

  3. Division of Medical Oncology, The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Canada

    Daniel Khalaf, Nathaniel Bouganim & Mark Clemons

  4. Instituto Tecnológico Autónomo de México, Ciudad de México, Mexico

    Berenice Baez-Revueltas

  5. Princess Margaret Hospital, Toronto, Canada

    Farah Kassam & Katherine Enright

  6. Trillium Health Partners Peel Regional Cancer Centre, Mississauga, Canada

    Jeff Myers

  7. National Cancer Center Singapore, Duke-NUS, Singapore, Singapore

    Rebecca Dent

Authors
  1. Cynthia Villarreal-Garza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Khalaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nathaniel Bouganim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark Clemons
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Omar Peña-Curiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Berenice Baez-Revueltas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alexander Kiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Farah Kassam
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Katherine Enright
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sunil Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kathleen Pritchard
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jeff Myers
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Rebecca Dent
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rebecca Dent.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Villarreal-Garza, C., Khalaf, D., Bouganim, N. et al. Platinum-based chemotherapy in triple-negative advanced breast cancer. Breast Cancer Res Treat 146, 567–572 (2014). https://doi.org/10.1007/s10549-014-3033-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-014-3033-4

Keywords

Search

Navigation